靶向治疗的严重副作用。 - Suppr | 超能文献

Severe side effects of targeted therapies.

作者信息

Mössner Rotraut

出版信息

J Dtsch Dermatol Ges. 2022 Jun;20(6):747-748. doi: 10.1111/ddg.14827.

DOI:10.1111/ddg.14827

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Severe side effects of targeted therapies.靶向治疗的严重副作用。

J Dtsch Dermatol Ges. 2022 Jun;20(6):747-748. doi: 10.1111/ddg.14827.

2

Complications of targeted drug therapies for solid malignancies: manifestations and mechanisms.实体恶性肿瘤靶向药物治疗的并发症：表现与机制。

AJR Am J Roentgenol. 2013 Mar;200(3):475-83. doi: 10.2214/AJR.12.9049.

3

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary.接受免疫检查点抑制剂治疗患者免疫相关不良事件的管理：美国临床肿瘤学会临床实践指南摘要

J Oncol Pract. 2018 Apr;14(4):247-249. doi: 10.1200/JOP.18.00005. Epub 2018 Mar 8.

4

Side effects of targeted therapies. Introduction.

Semin Oncol Nurs. 2014 Aug;30(3):137-8. doi: 10.1016/j.soncn.2014.05.001.

5

Pigmentary changes in patients treated with targeted anticancer agents: A systematic review and meta-analysis.接受靶向抗癌药物治疗患者的色素沉着变化：一项系统评价和荟萃分析。

J Am Acad Dermatol. 2017 Nov;77(5):902-910.e2. doi: 10.1016/j.jaad.2017.06.044. Epub 2017 Sep 14.

6

Risk of serious adverse event and fatal adverse event with molecular target anticancer drugs in cancer patients: A meta-analysis.癌症患者使用分子靶向抗癌药物发生严重不良事件和致命不良事件的风险：一项荟萃分析。

J Cancer Res Ther. 2019;15(7):1435-1449. doi: 10.4103/jcrt.JCRT_577_18.

7

Genetic polymorphisms associated with adverse reactions of molecular-targeted therapies in renal cell carcinoma.遗传多态性与肾细胞癌分子靶向治疗的不良反应相关。

Med Oncol. 2018 Jan 4;35(2):16. doi: 10.1007/s12032-017-1077-0.

8

Molecular and Clinical Approach to Intra-abdominal Adverse Effects of Targeted Cancer Therapies.靶向癌症治疗的腹腔内不良反应的分子与临床研究方法

Radiographics. 2017 Sep-Oct;37(5):1461-1482. doi: 10.1148/rg.2017160162. Epub 2017 Jul 28.

9

Managing Adverse Events With Immune Checkpoint Agents.使用免疫检查点抑制剂管理不良事件。

Cancer J. 2016 Mar-Apr;22(2):121-9. doi: 10.1097/PPO.0000000000000186.

10

Bevacizumab-associated diverticulitis: results of disproportionality analysis.贝伐单抗相关性憩室炎：不成比例分析结果

Expert Rev Clin Pharmacol. 2015 May;8(3):271-2. doi: 10.1586/17512433.2015.1041850.

引用本文的文献

1

Feiyiliu Mixture sensitizes EGFR mutant non-small cell lung cancer to osimertinib by attenuating the PRC1/Wnt/EGFR pathway.肺抑瘤合剂通过减弱PRC1/Wnt/EGFR信号通路使表皮生长因子受体（EGFR）突变的非小细胞肺癌对奥希替尼敏感。

Front Pharmacol. 2023 Jan 19;14:1093017. doi: 10.3389/fphar.2023.1093017. eCollection 2023.